A Multi-center, Open Label Phase II Trial of TKI258 in FGFR1 Amplified and Non-amplified Metastatic or Advanced HER2 Negative Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2015
At a glance
- Drugs Dovitinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 02 Apr 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 02 Apr 2012 Actual number of patients changed from 81 to 165 as reported by ClinicalTrials.gov.